In this double-blind trial , we randomly assigned @ patients with class II , III , or IV heart failure and an ejection fraction of @ % or less to receive either LCZ@ ( at a dose of @ mg twice daily ) or enalapril ( at a dose of @ mg twice daily ) , in addition to recommended therapy .